Literature DB >> 1985797

IgG subclass responses to human immunodeficiency virus-1 antigens: lack of IgG2 response to gp41 correlates with clinical manifestation of disease.

R B Lal1, I M Heiba, R R Dhawan, E S Smith, P L Perine.   

Abstract

To analyze differential antibody responsiveness of potential pathogenetic significance, sera from 66 patients with human immunodeficiency virus-1 (HIV-1) infections at various Walter Reed (WR) stages of the disease were analyzed to determine the subclass distribution of HIV antibodies. Although all IgG subclasses were involved in the HIV antibody response, the frequency was highest for IgG1 and the lowest for IgG4. When IgG subclass responses to different HIV antigens were compared qualitatively, IgG1 was the major subclass reactive with env, pol, and gag antigens; IgG2 and IgG3 were almost equally represented in response to gag gene products; and IgG4 showed minimal reactivity to p24 antigen in all HIV-infected patients regardless of their clinical presentation. In contrast, significantly lower levels of IgG2 anti-gp41 were observed in patients at WR 5 and 6 (5%) when compared to those at stage WR 1 and 2 (88%). The IgG2 response to a recombinant gp 120/41 antigen, however, remained unchanged, suggesting that the lack of IgG2 response may be associated with lack of responsiveness to the carbohydrate epitope on gp41. Indeed, parallel measurements of IgG antibody responses to group A carbohydrate were also lower in patients at WR 5 and 6 stages, without affecting antibody responses to polyribosyl ribitol phosphate and phosphocholine. As antibody responses to group A carbohydrate with its N-acetyl D-glucosamine (GlcNAc) determinant were lower at the WR 5 and 6 stage of HIV disease, GlcNAc may be one of the antigenic determinants on gp41 that plays a critical role in some of the pathologic events of HIV infection.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1985797     DOI: 10.1016/0090-1229(91)90141-v

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  9 in total

1.  Divergent antibody subclass and specificity profiles but not protective HLA-B alleles are associated with variable antibody effector function among HIV-1 controllers.

Authors:  Jennifer I Lai; Anna F Licht; Anne-Sophie Dugast; Todd Suscovich; Ickwon Choi; Chris Bailey-Kellogg; Galit Alter; Margaret E Ackerman
Journal:  J Virol       Date:  2013-12-18       Impact factor: 5.103

Review 2.  B cell responses to HIV and the development of human monoclonal antibodies.

Authors:  J E Boyd; K James
Journal:  Clin Exp Immunol       Date:  1992-05       Impact factor: 4.330

Review 3.  How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development?

Authors:  Per Johan Klasse; Rogier W Sanders; Andrea Cerutti; John P Moore
Journal:  AIDS Res Hum Retroviruses       Date:  2011-05-20       Impact factor: 2.205

4.  Plasma and salivary IgA subclasses and IgM in HIV-1-infected individuals.

Authors:  Xueling Wu; Susan Jackson
Journal:  J Clin Immunol       Date:  2002-03       Impact factor: 8.317

5.  Frequent Development of Broadly Neutralizing Antibodies in Early Life in a Large Cohort of Children With Human Immunodeficiency Virus.

Authors:  Amanda Lucier; Youyi Fong; Shuk Hang Li; Maria Dennis; Joshua Eudailey; Ashley Nelson; Kevin Saunders; Coleen K Cunningham; Elizabeth McFarland; Ross McKinney; M Anthony Moody; Celia LaBranche; David Montefiori; Sallie R Permar; Genevieve G Fouda
Journal:  J Infect Dis       Date:  2022-05-16       Impact factor: 7.759

6.  Phase I/II vaccination study of recombinant peptide F46 corresponding to the HIV-1 transmembrane protein coupled with 2.4 dinitrophenyl (DNP) Ficoll.

Authors:  S Schwander; M Opravil; R Lüthy; D G Hanson; J Schindler; A Dawson; B Letwin; M Dietrich
Journal:  Infection       Date:  1994 Mar-Apr       Impact factor: 3.553

Review 7.  HIV-1-specific antibody responses during acute and chronic HIV-1 infection.

Authors:  Georgia D Tomaras; Barton F Haynes
Journal:  Curr Opin HIV AIDS       Date:  2009-09       Impact factor: 4.283

8.  Distinct, IgG1-driven antibody response landscapes demarcate individuals with broadly HIV-1 neutralizing activity.

Authors:  Claus Kadelka; Thomas Liechti; Hanna Ebner; Merle Schanz; Peter Rusert; Nikolas Friedrich; Emanuel Stiegeler; Dominique L Braun; Michael Huber; Alexandra U Scherrer; Jacqueline Weber; Therese Uhr; Herbert Kuster; Benjamin Misselwitz; Matthias Cavassini; Enos Bernasconi; Matthias Hoffmann; Alexandra Calmy; Manuel Battegay; Andri Rauch; Sabine Yerly; Vincent Aubert; Thomas Klimkait; Jürg Böni; Roger D Kouyos; Huldrych F Günthard; Alexandra Trkola
Journal:  J Exp Med       Date:  2018-05-24       Impact factor: 14.307

9.  High-resolution definition of humoral immune response correlates of effective immunity against HIV.

Authors:  Galit Alter; Karen G Dowell; Eric P Brown; Todd J Suscovich; Anastassia Mikhailova; Alison E Mahan; Bruce D Walker; Falk Nimmerjahn; Chris Bailey-Kellogg; Margaret E Ackerman
Journal:  Mol Syst Biol       Date:  2018-03-26       Impact factor: 11.429

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.